The bill was sponsored by another candidate for president, Sen. Kamala Harris, D-Calif., according to the report.
If passed, the agency would regulate prices set by pharmaceutical companies, and it would have the authority to end exclusivity protections on drugs if companies do not set fair prices, according to the report. The House is voting next month on a bill that would authorize Medicare to negotiate drug prices.
Read more here.
More articles on leadership and management:
Moody’s chief economist: Numbers check out on Warren’s ‘Medicare for All’ funding plan
Are you a CEO with anxiety, depression? You’re not alone
Former Microsoft exec to chair advisory board for University of Washington’s Population Health Initiative
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
